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Abstract
The Pandemic of COVID-19 has been thoroughly followed and discussed on 
many levels due to the high level of attention that it has brought by its effect on the 
world. While this disease might seem like to arise out of the blue, we will shed light 
on COVID-19 disease which is caused by the virus SARS-CoV2 and belong to family 
of coronaviruses. We will discuss current knowledge about SARS-CoV2 emergence, 
diagnosis, its mode of action, and genomic information, For an antiviral treatment 
to be used, it should be preceded by a foundation of information about the virus 
genome and its family as discussed in this review.
Keywords: Covid-19, SARS-COV-2, genome, evolution, immunopathology, 
phylogenetic
1. Introduction
The Coronaviridae have a wide variety of host species, which infect many 
mammalian and avian species and result in high respiratory, hepatic, and central 
nervous system diseases. Coronaviruses in humans and fowl mainly cause infections 
in the upper respiratory tract and enteric infections are caused by pig and bovine 
Coronavirus [1]. Coronaviruses CoVs are divided into four genera and in 1937 the 
first coronavirus was identified [2, 3]. Coronaviruses are a family of helical nucleo-
capsid and extremely large genomes enveloped positive-stranded RNA viruses. 
Coronaviruses are composed of: 1) Nucleocapsid Protein (N): helical nucleocapsid 
protein component and is supposed to bind genomic RNA in a bead-on-string mode. 
2) spike protein (S): Viral envelope component that mediates binding to the receptor 
and merging of cell membranes if the virus and host. 3) Membrane Protein (M): 
the most present component and gives its form to the virion envelope. 4) Envelope 
Protein (E): A small, only minor component of virions and a small polypeptide 
between 8.4 and 12 kDa (76–109 amino acids). 5) Accessory Proteins: “Extra” genes 
may be interspersed with a group of canonical genes, replicase, S, E, M, and N with 
additional ORFs, or embedded in a separate ORF or heavily overlapped with another 
gene [4]. (Figure 1) Coronaviruses are also one of the few genomically proof-
reading RNA viruses that avoid the virus developing mutations that could weaken it. 
Such capacity may have contributed to the failure of specific antivirals like ribavirin 
to subdue SARS-CoV-2 meanwhile, can thwart viruses like hepatitis C. Drugs kill 
viruses by mutations. However, the proofreader can eliminate these changes in 
coronaviruses. Coronaviruses have a special trick that is fatal: they often recombine, 
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exchange pieces of RNA and other coronaviruses. This is usually an insignificant 
trade between viruses like parts [6]. Both mammals are affected by alphacorona-
viruses and beta-coronaviruses. Alpha-Coronaviruses and beta-Coronaviruses 
typically cause human breathing diseases and animal gastroenteritis. Gamma and 
delta coronaviruses infect birds, but some can infect mammals as well. The SARS-
CoV, MERS-CoV viruses, and the other four human coronaviruses (HCoV-NL-63, 
HCoV-229E, HCoV-OC43 and HKU1) are responsible for severe respiratory syn-
dromes in people with mild conditions in immunocompetent hosts, although some 
infections are severe in infants and elderly people [7]. Coronavirus transcription is 
characterized by the development of several mRNAs containing the sequences cor-
responding to the two ends of the genome. The production of subgenomic mRNA 
requires discontinuous transcripts. Transcription is known as the process by which 
subgenomical mRNAs are generated, and replications are the process by which 
genomic-sized RNA, which also acts as mRNA, is generated [8]. Human coronavi-
ruses (HCoV) were first detected and developed in the nasal cavities of common 
cold patients in the 1960s. Two human coronaviruses-OC43 and 229E are respon-
sible for about 30% of common colds [9, 10]. Middle East Coronavirus Respiratory 
Syndrome (MERS-CoV) has also been a global health concern. The initial report for 
MERS-CoV was in 2012. More than 2000 civilians have been infected in 27 countries 
in the Middle East and 4 subcontinents. During the SARS outbreak in 26 countries, 
more than 8000 cases were recorded in 2003 [11]. The ongoing coronavirus disease 
outbreak (COVID-19), first reported in December 2019 in Wuhan, China. As of 5th 
of April 2020, the world health organization (WHO) announced this disease as a 
global public health emergency to extend to 206 countries and territories across the 
world, with two international correspondence performed on 3,090,445 confirmed 
cases reported cases, including 217,769 deaths [12]. SARS-CoV-2 virus, the cause 
of COVID-19 disease that lead to an emergency outbreak that has been going for 
several months, now it may as well continue to its spread until the finding of new 
treatments along with the implementation of effective countermeasures. The newly 
evolving coronavirus (SARS-CoV 2) is becoming increasingly largescale. In the 
last few weeks, complete genomic sequences were released in order to understand 
the development and molecular characteristics of the virus by the global scientific 
community. In this review we will discuss the genomic structure of the virus, the 
Figure 1. 
Viral structure diagram showing the envelope, Centre and structure of the nucleoprotein. S, the spike protein 
and different drug candidates against the three coronaviruses [5].
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possible relations between several viruses of the same family and the suspected 
origins and spill over that might have led to such epidemic and molecular diagnostics 
used to detect.
2. Emergence of a new virus
The life of people over the centuries has been influenced by Zoonotic diseases. 
Many of these situations are especially variable in complexity, dynamics and shifts 
over time, as they emerge, and reappear. Transmission of the pathogen from an 
animal to human, also known as zoonotic spillovers, is a global public health issue 
and remains an ambiguous phenomenon, while associated with multiple outbreaks 
[13]. A mixture of many factors is needed to fulfill a zoonotic spillover, including 
ecological, epidemiological and behavioral determinants of pathogen transmission 
and inherent human factors influencing susceptible infection, as well as dietary 
and societal factors linked with foodborne zoonotic spillover [14]. A new virus is a 
virus that mutated and went through an evolution process to adapt to new kinds of 
hosts by a process called spillover. Spillover can happen in wild animals’ market as 
a virus can mutate and go on infecting a new host where it further mutates within 
new host until it adapts to this new host and become infectious [15]. Over the past 
two decades, many outbreaks of Zoonotic diseases such as SARS, the Hendra virus 
and the Nipah virus have been related to the bat-borne viruses. The most definitive 
proof was included from the separation of the CoV from bats in China, there was 
over 98% similarity in the genome sequence to SARS-CoV, and can use SARS-CoV-
receptor ACE2 on cells of the human race. It is hard to evaluate the possibility for 
spillover of several similar SARS-CoV Bat CoVs as a result of infringing isolation of 
viruses, but it should be noted that a “consensus” virus developed through reverse 
genetics has high evidence of human infection it is clear that bats are the most 
likely original cause of the current 2019 CoV outbreak in Wuhan, China, which 
started in December 2019, continuing to spread to many city and province areas in 
China from a “wet market.” The probability of food transmission of derived animal 
products was also suggested, as it has recently been pointed out to affect the present 
epidemic as well as the chance of common near contact with animals (a not unusual 
scenario in these types of markets). Their possible adaptations may lead to new and 
stable reservoirs, such as human hosts. Those are ideas and problems arisen from 
the emerged SARS-CoV2, that immediately compares SARS-CoV and MERS-CoV 
with other beta-coronaviruses with similar natural, intermediate animal hosts with 
also the possibility of human-to-human transmission in comparison [13, 16].
3. Genomic characteristics
During infection, the genome has many roles. It first functions as mRNA that is 
translated into a huge polyprotein called replicase that involves a ribosomal frame-
shifting event for complete synthesis. The replicase is the only genome-derived 
translation product; all downstream ORFs are expressed by Subgenomic RNAs. 
Next, the genome is the replication and transcription template. Finally, the genome 
is involved in assembly, as progeny genomes are found in progeny viruses [4]. The 
genomic RNA for coronavirus of about 30 000 nucleotides encodes structural virus 
proteins, non-structural proteins with a key part in viral RNA synthesis (which 
is understood to be replicase transcriptase proteins) and non-structural proteins 
that are not necessary for viral replication in cell culture but which in vivo tend 
Cell Interaction - Molecular and Immunological Basis for Disease Management
4
to be a selective advantage (which is referred to in vivo) [8]. Cis-acting sequence 
and structural elements involved in the replication, transcription, translation, 
and packaging are incorporated within RNA virus genomes. Some of these signals 
are intended to enable the interaction of selective viral RNAs with RNA synthesis 
machines while some allow or modify events that happen meanwhile the synthesis 
or assembly of viral protein [17, 18]. Coronaviruses contain the hugest genomes of 
any RNA virus, and this has hindered the production of full-length coronavirus 
cDNAs along with the discovery that certain cDNAs originating in the replicase 
areas of genes are unstable in bacteria. However, the assembly of long-lasting 
cDNAs in porcine coronavirus transmissible gastroenteritis viral genomic RNA 
(TGEV) has reportedly been identified with two methods. First, a TGEV full-length 
cDNA was installed on a bacterial artificial chromosome (BAC). Second, the TGEV 
total cDNA was installed in-vitro using a series of adjacent cDNAs within it engi-
neered unique restriction sites, cDNA of the RNA transcripts derived from bacte-
riophage T7-RNA polymerase have been then used for infectious virus production 
[19]. SARS-CoV-2 (Figure 2) has a long genome with ORF1ab polyprotein, along 
with four main structural proteins, involving Spike surface glycoprotein, small 
envelope protein, matrix protein and nucleocapsid protein, which is also the case in 
other beta-coronaviruses (Figure 3; Table 1). In the ORF1ab polyprotein there were 
two deletions (three nucleotides and 24 nucleotides) and also one at the 3′ end of 
the genome (ten nucleotides) [21] (Figure 4).
Figure 2. 
The structure of SARS-CoV-2 transcriptome [20].
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3.1 Transfection
The unusual variations in host diversity and tissue tropism between corona-
viruses are primarily due to differences in the spike glycoprotein. The S protein 
is a broad, glycoprotein type I membrane containing disruptive functional fields 
near the amino (S1) and carboxy (S2) Termini. Via their receptor specificity and 
probably by their membrane fusion activities in the cell entry of viral tropism, 
these spikes can be identified [1]. ACE2 is a primary determinant for the SARS-
CoV Host range [23, 24]. The life cycle of COVID-19 starts with the binding 
of its Angiotensin Converting Enzyme (ACE2) receptor expressed in various 
Figure 3. 
SARS-CoV-2 binding by its spike protein to ACE2 receptor [12].
Figure 4. 
SARS-CoV-2 inner proteins illustration [12].
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cell types in the body and other susceptible cells throughout the body. (ACE2), 
the membrane-associated enzyme Carboxypeptidase, is a crucial regulator for 
cardiac function. Now, recognized and characterized with a sudden second role 
for ACE2 in mediating viral entry and cell fusion in the form of SARS-CoV spike 
glycoprotein partner. The coronaviridae family includes this zoonotic virus. The 
virus has a healthy ssRNA genome and little structural and non-structural pro-
tein. Different points of view have been identified with great similarity to SARS-
CoV. The Approach of the virus is through S1 protein, which then integrates to the 
virus membrane with endosomal membranes, possibly by S2 mediation. Then the 
viral genome is released into the cytoplasm of the cell [25–30]. S-protein has two 
sub-units with one sub-unit directly binding to the receptor enabling the entrance 
of the virus into cells. The S-protein RNA binding domain in COVID-19 has a 
more advanced SARS-CoV homology. Although some of the residues essential to 
binding are not alike, the structural conformation was not changed in general by 
the non-identical residues [31]. CoV spike (S) is a key goal for vaccines, antibod-
ies and diagnosis. A 3.5 angle-resolution cryo-electron microscopy structure 
for the SARS-CoV-2 S was developed cutting conformation in order to promote 
medical response. The prominent trimer ‘s state possesses rotation in a receptor-
accessible conformation in one of the three receptor binding domains (RBDs). 
Biophysical and structural verification is also given that the SARS-CoV-2 S 
protein has more affinity than severe acute respiratory (SARS)-CoV S-binding 
enzyme 2, (ACE2) [32] (Figure 5).
3.2 Replication
Untranslated regions of RNA (UTRs) have 5′ and 3′ viruses that carry 
RNA-specific signals. The 5′ capped coronavirus genome compromise a 3’ UTR 
Group 1
Human coronavirus 229E HCoV-229E
Porcine enteric (transmisible gastroenteritis virus, TGEV; and porcine 
epidemic diarrhea virus, PEDV) and respiratory (PRCoV) coronavirus
PCoV
Canine coronavirus CCoV
Feline coronavirus, including feline infectious peritonitis virus (FIPV) FCoV
Group 2
Human coronavirus OC43 HCoV-OC43
Bovine coronavirus BCoV
Turkey coronavirus BCoV related TCoV-B
Murine coronaviruses including mouse hepatitis virus (MHV) MCoV
Porcine hemagglutinating encephalomyelitis virus HEV
Rat coronavirus including sialodacryoadenitis virus (SDAV) RtCoV
Group 3
Avian coronavirus including infectious bronchitis virus (IBV) ACoV




Some of coronaviridae family members [22].
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consisting of 300 to 500 nucleotides) in addition to a poly(A) tail. Host-related 
factors involving two class-II viruses bovine coronavirus (BCV) and Mouse 
Hepatitis Coronavirus (MHV) were studied, in order to better understand corona-
virus replication. Using gel mobility shift assays unique host protein interactions 
were identified with BCV 3’ UTR [287 nt plus poly(A) tail]. The MHV 3′ -UTR 
[301 nt in addition to poly(A) tail] rivalry indicates that interactivity for the two 
viruses are preserved. UV cross-linking studies observed proteins with molecular 
masses of 99, 95 and 73 kDa. The ranges 40- to 50 and 30 kDa even contained less 
heavily labeled proteins. For binding the 73-kDa protein a poly(A) tail was needed. 
The 73 kDa proteins have been identified as cytoplasmic poly(A)-binding protein 
(PABP) by an Immuno-precipitation of UV-cross-linked proteins. To define the 
significance of the poly(A) tail, the replication of the impaired genomes BCV Drep 
and MHV MIDI-C was used alongside with several mutants. After transfection 
to the supporting virus-infected cells, the defect genomes with shortened, 5- or 
10-A poly(A) tails have been replicated. BCV Drep RNA lacking a poly(A) tail did 
not replicate while MHV MIDI-C RNA replication was detected with a deleted tail 
after multiple mutations of the virus. The kinetics of replication is delayed in both 
mutants. Noticeable extension or addition of the poly(A) tail in mutants in the 
replication assay associated with the presence of these RNAs. RNAs exhibit less in 
vitro PABP binding in shorted Poly(A) tails, indicating decreased RNA replica-
tion interactions with protein. The data show strongly that the poly(A) tail is a 
significant indication for the replication of coronavirus [34]. The virus initiates 
replication and assembly of protein that is followed by the release of new infec-
tious particles into novel target cells. These events are followed by proinflamma-
tion chemokines and cytokines producing and triggering which lead to significant 
pulmonary damage-causing atypical pneumonia with quick abnormalities and 
failure [35, 36].
Figure 5. 
Phylogenetic tree of 160 SARS-CoV-2 genomes [33].
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3.3 Transcription
For differing coronaviruses, the number of mRNAs varies. The number of 
mRNAs in the coronavirus species is the number of functional genes. A few hours 
after infection with the virus in most viral cell systems, coronavirus mRNA synthe-
sis can be identified and proceeded until cells have become invasive. Subgenomic 
mRNAs are found to be heterogeneous (M. [37]). A two-component support based 
on expression system was developed and individual genomes were created by selec-
tive recombination or by using infectious cDNA clones. Transcription sequences 
have mainly been characterized by helper-dependent expression systems and can 
now be validated via single genomes. The coronavirus genome was created through 
modification of infectious cDNA, resulting in efficient expression of the foreign 
gene (20 g ml − 1) and stable (20 passages) [22, 38]. In a Study, The creation of 
the full-length infectious cDNA clone and a functional duplicate of the Urbani 
strain as a bacterial artificial chromosome (BAC) of the extreme acute respiratory 
syndrome (SARS-CoV). Through this method, the viral RNA was expressed in the 
cytomegalovirus promoter’s cell nucleus and further multiplied by viral replicas in 
the cytoplasm. The Escherichia coli infectious clone and duplicate have been com-
pletely stable. The use of the SARS-CoV replica has been shown to be important in 
efficient coronavirus-RNA synthesis for the recent identification of RNA-processes 
enzyme exoribonuclease, endo-ribonucleases and 2-line-O-ribose that are found 
to be essential [39]. The RNA-dependent RNA synthesis is used for coronaviral 
transcription. The result is that a nested range of 6 to 8 mRNAs of different sizes is 
produced, depending on the strain of the coronavirus. The mRNAs are five prime 
and three prime genome -co- terminals. The most significant mRNA is the genomic 
RNA (gRNA) for both rep1a and rep1b genes. A discontinuous transcription process 
fuses a lead sequence of 93 nucleotides) (originating from the 5 prime at the end 
of a genome to 5 prime of the mRNA coding sequence (body) [40]. The RNA virus 
genomes are comprised of a series of cis-acting and structural elements involved 
in viral replication. A bulky secondary loop structure was previously established at 
the upstream end of the 3-way untranslated region (3 tablets of UTR) of the Mouse 
Hepatitis Virus (MHV) coronavirus genome. This element has proved to be impor-
tant for viral replication, beginning immediately downstream of the nucleocapsid 
gene stop codon. A 3 UTR pseudoknot of the corresponding downstream closely 
related to the bovine coronavirus BCoV. It is an essential pseudoknot for replica-
tion and has a preserved counterpart for each coronavirus in groups 1 and 2 [17]. 
More than one ORF is comprised of 5 ‘unique regions within multiple mRNA s. For 
example, mRNA 5 of MHV, which has two ORFs in the coding region which can 
encode two p 1 3 and pl0 proteins, respectively. A negative-stranded RNA template 
that is represented in an only very small percentage (1–2%) of the intracellular 
virus-specific RNAs is clearly mediated for Coronavirus RNA synthesis. This nega-
tive strand was synthesized by the virus-encoded RNA from the inbound virion. 
This is likely because the positive-sequenced RNA exceeds the negative-stranded 
RNA for several rounds of mRNA synthesis. Thus, negative-stranded RNA has 
more stability. This stability is attributed to the presence in the coronavirus-
infected cells of all of the negatively-stranded RNA as a double-stranded RNA 
[41–43]. The transcriptome Structure was unknown despite the SARS-CoV-2 
genome being recorded recently. a high-resolution map was presented of the SARS-
CoV-2 transcriptome and epitranscriptome using two complementary sequencing 
techniques. DNA nanoball sequencing reveals that due to discontinuous transcrip-
tion occurrences the transcriptome is highly complexSARS-CoV-2 yields transcripts 
that code unknown ORFs with fusion, deletion and/or frameshift in addition to 
the canonical genomic and 9 subgenomic RNAs. 41 sites for RNA modification on 
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viral transcripts were also found with the most common motif being AAGAA with 
nanopore direct RNA sequencing [20].
3.4 Morphogenesis
Expression studies showed that coronavirus envelope protein E and the more 
present membrane glycoprotein M were required and adequate to assemble virus 
particles into cells. Clustered charged-to-alanine Mutagenesis of the gene E was 
carried, which integrated mutations in mouse hepatitis virus E (MHV) E protein, 
as a step forward in our understanding of the role of the mouse hepatitis virus E 
(MHV) E protein. One was apparently lethal and one was a wild-type phenotype of 
four probable clustered charged-to-alanine E gene mutants. The other two mutants 
were partly affected by temperature, developing tiny plaques at a nonpermissive 
temperature. Reverting analyses of these two mutants showed that each mutation 
was the reason for the temperature-sensitive phenotype and promoted probable 
interactions among E protein monomers. In permissive temperature, both temper-
ature-sensitive mutants have been substantially thermolabile, indicating that their 
assembly fails. In the case of the electron microscopy, virions of one of the mutants 
were discovered to have remarkably aberrant morphology when compared with 
the wild type: most mutant virions had pinched and extended forms that were seen 
seldom in the wild [44–46]. Specific recombination of RNA was utilized to create 
mutants containing chimeric nucleocapsid (N) protein genes in mouse hepatitis 
virus (MHV) that replace bovine coronavirus N gene segments in place of the 
correct MHV sequences. This described portions of the two N proteins which were 
functionally equivalent, given evolutionary divergences. These regions included 
mostly the RNA binding domain centrally located and two putative spacers con-
necting the three N protein domains. On the other hand, a bovine coronavirus 
cannot be transferred from the amino terminus N, the acidic carboxy-terminal 
region and the central domain serine and arginine-rich section, probably because 
these parts of a molecule are engaged in protein–protein interactions that are unique 
to each virus (or possibly each host). The results show that the recombination of the 
coronavirus genome can be used to produce extensive substitutions and recombi-
nants that cannot otherwise be produced between two viruses separated by species 
barrier [47].
4. Mutations
RNA viruses must establish an equilibrium between the adaptability to new 
environmental circumstances or the necessity to preserve the intact and replica-
tive genome to ensure survival and propagation for the host cells. Various virus 
families with the biggest and most complex replicating RNA genomes identified, 
up to 32 kb of positive RNA, such as coronaviruses, can achieve these objectives. 
CoVs, including (MHV) and SARS-CoV, express 3 to 5′ of exoribonuclease (ExoN) 
activity in nsp14. The exoN genetic inactivation of alanine replacement with 
retained active DE-D Residues in Engineered SARS-CoV and MHV Genomes leads 
to viable mutants, which display 15 to 20 times higher mutation rates and up to 
18 times higher than those endured for other RNA fidelity mutants. Nsp14-ExoN, 
therefore, is important for the fidelity of the replication and possibly acts as a direct 
mediator or regulator for a more complex RNA proof-reader, an exceptional process 
in RNA virus biology. The removal of nsp14-mediated proofreading mechanisms 
will have significant consequences for our interpretation of RNA virus evolution 
and will also provide a robust model to research the correlation between fidelity, 
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diversity and pathogenesis [48–52]. COVID-19 is very related to SARS-CoV Middle 
East Respiratory Syndrome (MERS). Yet another human attack by coronaviruses. A 
research attempted to explore potential changes/developments in the ‘spike protein’ 
element that enables the virus to bind to cell receptor(s) and in the silicon design 
and discovery of B epitopes in which antibody synthesis is used to neutralize and 



















































Mutations of SARS-CoV-2 strains found throughout the whole genome. The number in the parentheses shows 
where amino acid is found in its protein [21].
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21316G > A Orf1ab D7018N Missense
MN996527 30/Dec/2019-China
Wuhan
24292A > G S Synonymous 
mutation
LC528232 10/Feb/2020-Japan 11083 T > G Orf1ab L3606F Missense




28144 T > C ORF8 L84S Missense
LR757998 12/26/2019-China
Wuhan
6968C > A Orf1ab L2235I Missense
LR757998 12/26/2019-China
Wuhan








28144 T > C ORF8 L84S Missense
MN938384 1/10/2020-China
Shenzhen
29095C > T N Synonymous 
mutation
MN975262 11/Jan/2020-China 8782C > T Orf1ab Synonymous 
mutation
MN975262 11/Jan/2020-China 9534C > T Orf1ab T3090I Missense
MN975262 11/Jan/2020-China 29095C > T N Synonymous 
mutation
MN975262 11/Jan/2020-China 28144 T > C ORF8 L84S Missense




28144 T > C ORF8 L84S Missense
MN994467 23/Jan/2020-USA
CA
1548G > A Orf1ab S428N Missense
MN994467 23/Jan/2020-USA
CA








28077G > C ORF8 V62L Missense
MN994467 23/Jan/2020-USA
CA
28144 T > C ORF8 L84S Missense
MN994467 23/Jan/2020-USA
CA




1912C > T Orf1ab Synonymous 
mutation
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8388A > G Orf1ab N2708S Missense
GWHABKF00000001 23/Dec/2019-China
Wuhan
8987 T > A Orf1ab F2908I Missense
GWHABKK00000001 30/Dec/2019-China
Wuhan




21316G > A Orf1ab D7018N Missense
GWHABKH00000001 30/Dec/2019-China
Wuhan
6996 T > C Orf1ab I2244T Missense
GWHABKJ00000001 01/Jan/2019-China
Wuhan
7866G > T Orf1ab G2534V Missense
GWHABKM00000001 30/Dec/2019-China
Wuhan
21137A > G Orf1ab K6958R Missense
GWHABKM00000001 30/Dec/2019-China
Wuhan
7016G > A Orf1ab G2251S Missense
GWHABKO00000001 30/Dec/2019-China
Wuhan
8001A > C Orf1ab D2579A Missense
GWHABKO00000001 30/Dec/2019-China
Wuhan
9534C > T Orf1ab T3090I Missense
MT188341 05/Mar/2020-USA
MN




























28144 T > C ORF8 L84S Missense
MT188339 09/Mar/2020-USA
MN




17423A > G Orf1ab Y5720C Missense
MT188339 09/Mar/2020-USA
MN




21386C > T Orf1ab Synonymous 
mutation
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28144 T > C ORF8 L84S Missense
MT121215 02/Feb/2020-China
Shanghai








29095C > T N Synonymous 
mutation
MT126808 2/28/2020-Brazil 26144G > T ORF3a G251V Missense
MT066175 31/Jan/2020-Taiwan 8782C > T Orf1ab Synonymous 
mutation
MT066175 31/Jan/2020-Taiwan 28144 T > C ORF8 L84S Missense
MT093571 07/Feb/2020-Sweden 13225C > G Orf1ab Synonymous 
mutation
MT093571 07/Feb/2020-Sweden 13226 T > C Orf1ab Synonymous 
mutation
MT093571 07/Feb/2020-Sweden 17423A > G Orf1ab Y5720C Missense
MT093571 07/Feb/2020-Sweden 23952 T > G S Synonymous 
mutation
MT066156 30/Jan/2020-Italy 11083 T > G Orf1ab L3606F Missense
MT066156 30/Jan/2020-Italy 26144G > T ORF3a G251V Missense
LC522975 20/JAN/2020-JAPAN 8782C > T Orf1ab Synonymous 
mutation
LC522975 20/JAN/2020-JAPAN 29095C > T N Synonymous 
mutation
LC522975 20/JAN/2020-JAPAN 28144 T > C ORF8 L84S Missense
LC522975 20/JAN/2020-JAPAN 2662C > T ORF1ab Synonymous 
mutation
LC522974 20/JAN/2020-JAPAN 8782C > T ORF1ab Synonymous 
mutation
LC522974 20/JAN/2020-JAPAN 29095C > T N Synonymous 
mutation
LC522974 20/JAN/2020-JAPAN 28144 T > C ORF8 L84S Missense
LC522974 20/JAN/2020-JAPAN 2662C > T ORF1ab Synonymous 
mutation
LC522973 20/JAN/2020-JAPAN 8782C > T ORF1ab Synonymous 
mutation
LC522973 20/JAN/2020-JAPAN 29095C > T N Synonymous 
mutation
LC522973 20/JAN/2020-JAPAN 3792C > T ORF1ab A1176V Missense
LC522973 20/JAN/2020-JAPAN 29095C > T N Synonymous 
mutation
LC522973 20/JAN/2020-JAPAN 2662C > T ORF1ab Synonymous 
mutation
LC522973 20/JAN/2020-JAPAN 28144 T > C ORF8 L84S Missense
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LC522972 20/JAN/2020-JAPAN 29303C > T N P344S Missense
LC522972 20/JAN/2020-JAPAN 25810C > G ORF3a L140V Missense
LC522972 20/JAN/2020-JAPAN 11557G > T ORF1ab E3764D Missense
LC522972 20/JAN/2020-JAPAN 15324C > T ORF1ab Synonymous 
mutation
LC521925 21/JAN/2020-JAPAN 1912C > T ORF1ab Synonymous 
mutation
LC521925 21/JAN/2020-JAPAN 18512C > T ORF1ab P6083L Missense

















490 T > A ORF1ab D75E Missense
MN988713 21/JAN/2020-USA
Chicago
3177C > T ORF1ab P971L Missense
MN988713 21/JAN/2020-USA
Chicago
28854C > T N S194L Missense
MN988713 21/JAN/2020-USA
Chicago
28077G > C ORF8 V62L Missense
MN988713 21/JAN/2020-USA
Chicago
28144 T > C ORF8 L84S Missense
MN997409 21/JAN/2020-USA
Arizona








11083G > T ORF1ab L3606F Missense
MN997409 21/JAN/2020-USA
Arizona
28144 T > C ORF8 L84S Missense
MT072688 26/JAN/2020-USA: 
Massachussetts




27493C > T ORF7a P34S Missense
NMDC60013002–09 01/JAN/2019-China
Wuhan








11764 T > A ORF1ab N3833K Missense
NMDC60013002–06 30/Dec/2019-China
Wuhan




28144 T > C ORF8 L84S Missense
Table 3. 
Coding mutation list detected in SARS-CoV-2 genomes [57].
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the sequences of proteins obtained worldwide. Some B epitopes (part of an antigen 
molecule to which an antibody attaches itself), 177-MDLEGKQGNFKNL-189-555- 
SNKKFLPF-562-656 -VNSYECDIPI-666, 1035- GQSKRVDFC-1043, from the Cons 
sequence constructed from global protein sequences released between 11 Feb and 
06 April, have been found to meet most of the criteria required for real wet applica-
tion [53]. SARS-CoV is well suited to cultural development and does not seem to be 
selected in humans. It was also assessed that, in late October 2002, the alleged root 
of the SARS outbreak was consistent with a previous report of case use from China. 
The higher structural and antigenic sequence divergence and significant deletions 
within 3 ‘– of much of the viral genome indicate that some selection pressures 
conflict along with the functional structure of these confirmed and suspected 
ORFs [54]. In three regions the SARS and SARSr of bats-CoVs are largely different: 
S, ORF8 and ORF3. SARSr-CoVs bats share high sequence with the SARS- COV in 
the S2 but are highly different in the S1 region. However, bat MERSr-CoVs bats and 
human and camel MERS-CoVs share similar genomics but are significantly differ-
ent from their genomic sequences [7]. Comparison of COVID-19, SARS-CoV and 
MERS-CoV genome sequence showed that COVID-19 has better sequence similarity 













































Non-coding mutation list detected in SARS-CoV-2 genomes [57].
17
SARS-CoV-2 and Coronavirus Ancestors under a Molecular Scope
DOI: http://dx.doi.org/10.5772/intechopen.95102
with SARS-CoV compared to MERS CoV. Nevertheless, the COVID-19 amino acid 
sequence differed from the other coronavirus in specific areas of 1ab polyprotein 
and surface glycoprotein or S-protein [31]. Considering the high rate of mutation 
that characterizes RNA viruses, it is clear that several more mutations will emerge 
in the viral genome to monitor the spread of SARS-CoV-2 knowing that also their 
mutations rate are lower than other RNA viruses due to their proofreading activity 
described above [55, 56](Tables 2–4).
5. Evolution and origin
Most SARS-CoV strains are derived from bats. SARS-CoV bat is a probable 
progenitor for SARS – CoV that is contagious to humans and civets, and thus it  
is important to study ACE2 receptor for monitoring origins of SARS-CoV and 
avoiding and controlling the outbreak. Though palm civets were involved in SARS 
emergence, most early MERS index cases had contact with dromedary camels. 
Indeed, the MERS-CoV strains separated from camels were nearly matching to 
those from humans [7]. The virus shares 96% of its genetic material with a virus 
detected from a bat found in a cave in Yunnan in China. A persuasive argument that 
it comes from bats but there is a critical alteration. The coronaviral spike proteins 
have a unit called a receptor-binding domain that is essential to the successful 
entry of human cells. Especially powerful is the SARS-CoV-2 binding domain and 
it varies from the bat virus Yunnan which appears to not affect human. Another 
Complicating matter, a scaly anteater called the pangolin with a coronavirus 
which was almost similar to the human version with a receptor-binding domain. 
However, the majority of the coronavirus was genetically identical just 90%, and 
some researchers do not believe that pangolin was the intermediary. It is difficult to 
draw a family tree since both mutations and recombinations are involved [58–60]. 
An article identifies and uses a machine learning-based alignment-free approach 
to identify a COVID-19 intrinsic genomic signature for an ultra-fast, scalable, and 
extremely precise classification of all COVID-19 virus genomes. The technique 
presented incorporates supervised machine learning with MLDSP for genome 
analysis, improved by a machine learning component decision tree approach and 
a Spearman-leading correlation coefficient analysis of tests. These methods are 
used to examine a broad collection of more than 61.8 million bp, including the 
29 COVID-19 virus sequences on 27 January 2020, with over 5,000 unique viral 
genomic sequences. The findings endorse a bat hypothesis and the COVID-19 
virus is classed under Betacoronavirus as the Sarbecovirus. Without any advanced 
biological expertise, training or genome annotations, our method achieves a 100% 
precise classification of the COVID-19 virus sequences, and determines the most 
important relationships between more than 5000 genomes in minutes, from the 
beginning on, with the sole use of raw DNA sequence details [61]. In a recent 
research, they have developed a phylogenetic tree, including other members of 
coronaviridae including Bat coronavirus (BCoV) and extreme acute respiratory 
2019 disease, taking advantage of all of the available genomic knowledge. The clos-
est BCoV sequence, with a 96,2% sequence 2019 SARS-CoV2 identity, confirm that 
all available genomes of the sequence are of zoonotic origin. We have confirmed 
the high sequence similarity (> 99%) among all available genomes. Given the low 
2019 SARS-CoV2 heterogeneity, at least two genomic hyper various hotspots were 
identified, including one of the Serine/Leucine variations in viral ORF8 Protein 
encoded, can be detected [62]. (Figures 6 and 7) In the study a Malayan pangolin-
isolated coronavirus showed 100%, 98.6%, 97.8% and 90.7% SARS-CoV-2 amino 
acid identity in genes E, M, N, and S respectively. Particularly in the S protein of 
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Pangolin-CoV, the receptor-binding domain is nearly the same as the SARS-CoV-2 
with vital one-amino acid alteration. Results of comparative genomic analysis 
indicate that SARS-CoV-2 may have been the result of a Pangolin-CoV-like virus 
recombination with a Bat-CoV-RaTG13 virus [63].
6. Immunopathology of SARS-CoV2
Pneumonia, lymphopenia, drained lymphocytes and a cytokine storm are 
distinguishable symptoms of Extreme Coronavirus Disease 2019 (COVID-19). 
Major antibody development is detected, but it remains to be determined if this 
is defensive or pathogenic. Defining the immunopathological changes in COVID-
19 patients presents future drug development targets and is critical for clinical 
management [64]. Asymptomatic condition is found in a large but generally 
unexplained proportion of the infected people, analogous to many other viral 
diseases. Usually, a 1-week, self-limiting viral respiratory disease develops in most 
patients, and ends with the production of neutralizing antiviral T cell and antibody 
immunity [65]. SARS-CoV-2 has been shown to weaken natural immune responses, 
resulting in a compromised immune system and an unregulated inflammatory 
response in extreme and vital COVID-19 patients. These patients display lympho-
penia, stimulation and malfunction of lymphocytes, defects of granulocytes and 
monocytes, elevated levels of cytokines, and higher amounts of immunoglobulin G 
(IgG) and total antibodies [66] (Figure 8). Extreme and fatal COVID-19 is linked 
with lymphopenia and an elevated amount of blood neutrophils [67]. Lymphocyte 
counts of 800 cells/μl and a decreased probability of recovery are reported in 
ICU patients suffering from COVID-19. The mechanism of action and causes of 
Figure 6. 
A coronavirus phylogenetic tree based on full-length genome sequences. Both complete coronavirus genome 
sequences have been obtained from RefSeq, the NCBI reference sequence database [5].
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Figure 7. 
A phylogenetic tree with all the sequences of SARS- CoV2 available from the 02–Feb-2020 sequence in the blue 
divisions, plus six Bat coronavirus sequences split in multiple taxa, six human SARS sequences (green) and two 
MERS sequences (orange); the bootstrap percentage of each branch is recorded [62].
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lymphopenia in patients with COVID-19 are unclear, but SARS-like viral particles 
and SARS-CoV RNA have been observed in T cells, indicating that the SARS virus 
may have a detrimental influence on T cells via apoptosis [68]. Accumulating data 
proves the involvement of T cells in COVID-19 and possibly in the immunological 
memory that develops after recovering from infection with SARS-CoV-2. Many, 
but not always, hospitalized patients tend to have both CD8 + and CD4 + T cell 
responses, and research points to potential T cell responses consistent with extreme 
disease that are suboptimal, abnormal or otherwise inadequate [5]. In a report, a 
group of 452 patients with positive test results of COVID-19 in Wuhan, China shows 
dysregulated immune system. Boosts in NOD-like receptor (NLR) and T lympho-
penia, especially a decline in CD4 + T cells, were prominent in COVID-19 patients, 
and was even more noticeable in extreme cases, but the number of CD8 + cells and 
B cells did not change significantly. On the basis of these results, it was proposed 
that COVID-19 may affect lymphocytes, especially T lymphocytes, and that the 
immune system is disrupted during the infection period [69]. COVID-19 will 
lead to defects in the routine of peripheral blood parameters. The most noticeable 
anomalies that are linked to the intensity of the condition and clinical classification 
are the reduction in lymphocytes and the rise in the NLR ratio. The lower count and 
delay in eosinophil development can be indicators of weak COVID-19 outcomes. 
Thus, complex analysis of peripheral blood routine parameters has a significant 
reference point for COVID-19 progression and prognosis evaluation [70]. Also, In 
the different stages of COVID-19, multiple cell morphological modifications can 
be seen. In fact, a strong granulocytic reaction with immaturity, dysmorphism 
and apoptotic-degenerative morphology was apparent in peripheral blood in the 
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Cytokine storm plays a crucial role in infected individuals for the pathogenesis of 
many serious manifestations of the disease. Acute respiratory distress syndrome, 
thromboembolic disorders such as acute ischaemic strokes caused by myocardial 
infarction and large vessel occlusion, encephalitis, acute kidney damage, and vascu-
litis (childhood Kawasaki syndrome and adult renal vasculitis) [72]. Nonetheless, 
it is uncertain if serious illness is triggered by immune hyperactivity or inability 
to overcome an inflammatory reaction owing to continuing virus replication or 
immune dysregulation. However, records of elevated levels of thrombi produc-
tion and endothelial cell death in patients with COVID-19 suggest disruption to 
the vascular endothelium and the participation of cytokine elevated activity and 
immunothrombosis [73]. In response to infection as well as other triggers, cytokine 
storm is a general term referring to maladaptive cytokine release. The pathogen-
esis is complicated, but requires the depletion of regulated control at both local 
and systemic levels of proinflammatory cytokine output. The disease is rapidly 
progressing, and mortality is elevated. Some data suggests that dysregulated and 
uncontrolled cytokine release in certain COVID19 patients has been directly cor-
related with significant deterioration [74].
7. Molecular diagnostics
COVID-19 Test of SARS-CoV-2 is a real-time reverse transcription polymerase 
chain-reaction (PCR) in upper or lower respiratory samples for the qualitative iden-
tification of nucleic acid (such as nasal, nasopharyngeal or oropharyngeal swabs, 
sputum, lower respiratory tract aspirates, bronchoalveolar lavage, nasopharyngeal 
wash/aspirate or a nasal aspirate) that is individually obtained from those suspected 
of COVID-19 by their healthcare provider [75]. The latest COVID-19 outbreak can 
be detected using qPCR, but insufficient possession of reagents and equipment 
has hindered the identification of diseases. To assist in making COVID-19 more 
effective in our diagnostics, a new protocol was suggested for the application of the 
CRISPR-based SHERLOCK technique for detecting COVID-9. COVID-19 objectives 
were identified between 20 and 200 aM (10–100 copies per input microlitre) with 
the use of synthetic COVID- 19 virus RNA fragments. The test can be performed 
starting with patient-purified RNA as used in qRT-PCR trials and read in less than 
an hour with a dipstick, without the need for complex instrumentation [58, 59]. 
GolayMetaMiner, an in-house software, has identified four different regions over 50 
nucleotides for the SARS-CoV-2 genome with 96 SARS-CoV-2 and 104 non-SARS-
CoV-2 coronaviral genomes. Primers were made to target the longest and previously 
not targeted nsp2 region and tailored as a reverse transcription-polymerase chain 
reaction (RT-PCR) test without a probe. The new COVID- 19-nsp2 assay had a 
detection limit (LOD) of 1.8 TCID5 mL and did not intensify any human coronavi-
rus pathogens and respiratory viruses. The process threshold reproducibility (Cp) 
values have been adequate and overall imprecision (%CV) values have dropped far 
below 5%. The latest assay evaluation using 59 clinical samples from 14 reported 
cases demonstrated a 100% compliance with COVID-19-RdRp/Hel reference assay, 
which has been previously established. A COVID-19-nsp2, fast sensitive RT-PCR 
test was developed for SARS-CoV-2 [76].
8. Future perspectives of nucleic acid-based vaccines
Since COVID-19 is new to humanity and the essence of defensive immune 
responses is incompletely understood, it is unknown which vaccination techniques 
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are going to be most effective. Therefore, designing diverse vaccine platforms and 
methods in tandem is crucial. Indeed, researchers worldwide have been racing to 
produce COVID-19 vaccines since the epidemic started, with at least 166 vaccine 
candidates now in preclinical and clinical production (Draft landscape of COVID-
19 candidate vaccines, 2020). A new pandemic vaccine developing framework 
has been suggested to address the immediate need for a vaccine, compacting the 
development period from 10 to 15 years to 1 to 2 years [77]. Recombinant plasmid 
DNA has been investigated as a vaccine model, although lately, mRNA has appeared 
as a promising platform. Six mRNA-based COVID-19 vaccines and four DNA-based 
COVID-19 vaccines are currently in clinical trials, with 27 such vaccines (16 mRNA-
based and 11 DNA-based) undergoing preclinical production [78]. (Draft landscape 
of COVID-19 candidate vaccines, 2020). For protein translation and post-transla-
tional modifications, antigen-encoding mRNA encapsulated with a carrier such as 
lipid nanoparticles can be effectively conveyed in vivo into the cytoplasm of host 
cells, which is a plus over vaccines of the recombinant protein subunit. The mRNA 
vaccines are non - pathogenic and are synthesized without microbial molecules by 
in vitro transcription [79]. While no mRNA vaccine has been approved for human 
use yet, recent reports of influenza, rabies and Zika virus infections in animals 
support its promise in the covid-19 vaccine development race [80]. Plasmid DNA 
vaccines share many features, such as safety, ease of development and scalability, 
with mRNA vaccines, but with the differences of having poor immunogenic and 
having to be administered in several doses coupled with the addition of an adjuvant. 
This review provides valuable information that can be redirected to the purpose 
of working on these nucleic acid-based vaccines which provides a new propitious 
platform of vaccine production.
9. Conclusion
Coronaviruses have proven themselves to be prevailing and a very high threat 
to our existence by their unique features and ambiguity that caused catastrophic 
effects in this pandemic. It is obvious that coronaviruses have high spillover abili-
ties and adaptation to new hosts so that enables more appearances in future. For a 
vaccine to be made or an anti-viral drug to be produced, it is very mandatory that 
all is known about the virus family, virus genome and its own central dogma, how it 
differs from its predecessors, their similarities, mutation rates and screening meth-
ods. A treatment that will be effective, long-lasting and prepared for any mutation 
is needed to be able to fight this virus and eradicate this disease and prevent the 
emergence of a new pandemic by this family of potential and active killers (The 
Coronaviruses).
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